2025-522551-25-00RecruitingPhase 1
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics/Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus
Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Jul 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 1 Oct 2025
- Start date
- 1 Jul 2026
- Lead sponsor
- AstraZeneca AB
- Diseases
- Type 2 diabetes
- EU CT number
- 2025-522551-25-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 35
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes. It studies how the drug AZD6793 affects metformin in the body.
- Age
- 18 years and older
- Sex
- All sexes can join
- Disease stage
- Type 2 diabetes mellitus
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROFIL Institut fuer Stoffwechselforschung GmbH | Neuss | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.